Santini G, Contu A, Porcellini A, Chisesi T, Coser P, Congiu A M, Morandi S, Manna A, Schintu G M, Quaini R
Divisione di Ematologia I, Ospedale Civile, Genova, Italy.
Haematologica. 1991 Nov-Dec;76(6):485-90.
From October, 1986 to July 1989, 35 consecutive patients with high- and intermediate-grade non-Hodgkin's lymphoma, relapsed or refractory to first-line-anthracycline-containing regimens, were treated with mitoxantrone alone or in combination chemotherapy (VeMP: Ve = VP-16, M = Mitoxantrone, P = Prednisolone).
In the first 15 patients, treated with Mitoxantrone alone, complete response (CR) and partial response (PR) each occurred in 4 patients, for a total response rate of 54%. In the following 20 patients, treated with the VeMP regimen, CR occurred in 10 patients (50%), PR in 1. The overall three-year survival was 27% in the first group and 40% in the second. Acute toxicity was generally mild. No patient developed cardiac symptoms or other toxicities requiring discontinuation of therapy. Myelosuppression was the most important side effect, being more remarkable for patients treated with VeMP regimen.
Mitoxantrone, alone or in combination chemotherapy, appears to be a drug with significant activity in aggressive non-Hodgkin's lymphomas.
1986年10月至1989年7月，35例连续的中高度非霍奇金淋巴瘤患者，对含蒽环类药物的一线方案复发或难治，接受了米托蒽醌单药治疗或联合化疗（VeMP方案：Ve = 依托泊苷，M = 米托蒽醌，P = 泼尼松）。
在前15例仅接受米托蒽醌治疗的患者中，4例出现完全缓解（CR），4例出现部分缓解（PR），总缓解率为54%。在随后的20例接受VeMP方案治疗的患者中，10例（50%）出现CR，1例出现PR。第一组患者的三年总生存率为27%，第二组为40%。急性毒性一般较轻。没有患者出现心脏症状或其他需要停药的毒性反应。骨髓抑制是最重要的副作用，在接受VeMP方案治疗的患者中更为明显。
米托蒽醌单药或联合化疗，似乎是一种对侵袭性非霍奇金淋巴瘤有显著活性的药物。
